SH 2933 · Produits chimiques organiques
Composés hétérocycliques à hétéroatome d’azote
Données mises à jour le 18 octobre 2026 · données des listes 2026.10.2
En bref
Le droit de douane de l’UE sur les composés hétérocycliques azotés du Mercosur, aujourd’hui jusqu’à 5,2 %, tombe à zéro au plus tard en 2030 ; le droit de douane brésilien sur les composés hétérocycliques azotés en provenance de l’UE, aujourd’hui jusqu’à 11,8 %, tombe à zéro au plus tard en 2041 (dès 2036 pour la plupart des lignes, 1 ligne sur 243 est exclue).
Les taux en un coup d’œil
Vers l’UE depuis le Mercosur
43 lignes tarifairesDroit préférentiel 2026
0–5,2 %
Franchise sur toutes les lignes en démantèlement d’ici
2030
Taux de base de l’accord
0–6,5 %
Taux NPF appliqué aujourd’hui
0–6,5 %
Vers le Brésil depuis l’UE
243 lignes tarifairesDroit préférentiel 2026
0–12,6 %
Franchise sur toutes les lignes en démantèlement d’ici
2041
Taux de base de l’accord
0–14 %
Taux NPF appliqué aujourd’hui
0–12,6 %
Calculez le droit sur votre envoi
Ouvre le calculateur avec la position 2933 et le flux commercial déjà renseignés.
À propos de ce produit
Cette position couvre de nombreux principes actifs pharmaceutiques et intermédiaires agrochimiques. L’UE supprime ses droits dès le départ sur environ la moitié des lignes et en quelques années sur les autres. Le taux appliqué du Mercosur est déjà nul sur de nombreuses lignes, et les autres sont démantelées, avec une ligne exclue.
Comment le droit baisse, année après année
Droit ad valorem le plus élevé et le plus bas chaque année, sur les lignes qui vont vers zéro. Les lignes exclues ou couvertes uniquement par un contingent gardent leur droit et ne sont pas prises en compte.
Vers l’UE depuis le Mercosur
| Année | Droit ad valorem | Lignes en franchise |
|---|---|---|
| 2026 | 0–5,2 % | 21 / 43 |
| 2027 | 0–3,9 % | 21 / 43 |
| 2028 | 0–2,6 % | 21 / 43 |
| 2029 | 0–1,3 % | 21 / 43 |
| 2030 | 0 % | 43 / 43 |
Vers le Brésil depuis l’UE
| Année | Droit ad valorem | Lignes en franchise |
|---|---|---|
| 2026 | 0–11,8 % | 182 / 243 |
| 2027 | 0–11 % | 182 / 243 |
| 2028 | 0–10,2 % | 182 / 243 |
| 2029 | 0–9,4 % | 182 / 243 |
| 2030 | 0–8,6 % | 185 / 243 |
| 2031 | 0–7,8 % | 185 / 243 |
| 2032 | 0–7 % | 185 / 243 |
| 2033 | 0–6,3 % | 185 / 243 |
| 2034 | 0–5,5 % | 186 / 243 |
| 2035 | 0–4,7 % | 186 / 243 |
| 2036 | 0–3,9 % | 241 / 243 |
| 2037 | 0–3,1 % | 241 / 243 |
| 2038 | 0–2,3 % | 241 / 243 |
| 2039 | 0–1,5 % | 241 / 243 |
| 2040 | 0–0,7 % | 241 / 243 |
| 2041 | 0 % | 242 / 243 |
Lignes par catégorie de démantèlement
La catégorie de démantèlement fixe le rythme de la baisse : 0 signifie la franchise dès l’entrée en vigueur, 4 à 15 le nombre d’années avant le taux zéro, E l’exclusion, et les codes en lettres des contingents ou des traitements particuliers.
Mercosur → UE
- 4× 22
- 0× 21
UE → Mercosur
- 4× 180
- 10× 57
- 0× 3
- 8× 1
- 15× 1
- E× 1
Contingents tarifaires
Aucun contingent tarifaire ne s’applique à cette position.
Taux dans chaque pays du Mercosur
Chaque membre a son propre taux de base et son propre taux NPF appliqué. La préférence est calculée à partir du taux de base, ou du taux appliqué lorsqu’il est plus bas (article 2.4, paragraphe 7, de l’accord) ; le taux actuel peut donc varier d’un pays à l’autre.
| Pays | Taux de base | NPF appliqué | Préférentiel 2026 | Zéro en | Source du taux appliqué |
|---|---|---|---|---|---|
| Brésil | 0–14 % | 0–12,6 %2 lignes n’ont pas de taux publié unique | 0–12,6 % | 2041 | Brazil applied import duty, Res. Gecex 272/2021 Annexes II, V, VI, IX (MDIC), au 5 octobre 2026 |
| Argentine | 2–35 % | 0–12,6 %2 lignes n’ont pas de taux publié unique | 0–12,6 % | 2041 | Argentina applied import duty (DIE), ARCA Arancel Integrado, au 18 octobre 2026 |
| Uruguay | 2–14 % | 0–12,6 %2 lignes n’ont pas de taux publié unique | 0–12,6 % | 2041 | Uruguay applied import duty (Arancel Nacional, MEF), au 10 février 2025Copie manuellePlus de 180 jours |
| Paraguay | 0–14 % | 0–12,6 %2 lignes n’ont pas de taux publié unique | 0–12,6 % | 2036 | Paraguay applied import duty (Arancel Nacional Vigente, MEF), au 4 novembre 2025Copie manuellePlus de 180 jours |
Toutes les lignes tarifaires
Les désignations des lignes sont le texte anglais des listes (NC 2013 pour l’UE, NCM 2012 pour le Mercosur).
Vers l’UE depuis le Mercosur : 43 lignes
| Code | Désignation | Catégorie | Base | NPF appliqué | 2026 | Final |
|---|---|---|---|---|---|---|
| 2933 11 10 | Propyphenazone | 0 | Franchise | Franchise | Franchise | Franchise |
| 2933 11 90 | Phenazone "antipyrin" and its derivatives (excl. propyphenazone "INN") | 4 | 6,5 % | 0 % [additional code 2500] / 6.5 % [additional code 2501] | 5,2 % | Franchiseà partir de 2030 |
| 2933 19 10 | Phenylbutazone "INN" | 0 | Franchise | Franchise | Franchise | Franchise |
| 2933 19 90 | Heterocyclic compounds with nitrogen hetero-atom[s] only, containing an unfused pyrazole ring, whether or not hydrogenated, in the structure (excl. phenazone "antipyrin" and its derivatives and phenylbutazone "INN") | 4 | 6,5 % | 0 % [additional code 2500] / 6.5 % / 6.5 % [additional code 2501] | 5,2 % | Franchiseà partir de 2030 |
| 2933 21 00 | Hydantoin and its derivatives | 4 | 6,5 % | 0 % [additional code 2500] / 6.5 % / 6.5 % [additional code 2501] | 5,2 % | Franchiseà partir de 2030 |
| 2933 29 10 | Naphazoline hydrochloride "INNM" and naphazoline nitrate "INNM"; phentolamine "INN"; tolazoline hydrochloride "INNM" | 0 | Franchise | Franchise | Franchise | Franchise |
| 2933 29 90 | Heterocyclic compounds with nitrogen hetero-atom[s] only, containing an unfused imidazole ring, whether or not hydrogenated, in the structure (excl. hydantoin and its derivatives, naphazoline hydrochloride "INNM", naphazoline nitrate "INNM", phentolamine (onn) and tolazoline hydrochloride "innm") | 4 | 6,5 % | 0 % [additional code 2500] / 6.5 % / 6.5 % [additional code 2501] | 5,2 % | Franchiseà partir de 2030 |
| 2933 31 00 | Pyridine and its salts | 4 | 5,3 % | 5,3 % | 4,2 % | Franchiseà partir de 2030 |
| 2933 32 00 | Piperidine and its salts | 4 | 6,5 % | 6,5 % | 5,2 % | Franchiseà partir de 2030 |
| 2933 33 00 | Alfentanil "INN", anileridine "INN", bezitramide "INN", bromazepam "INN", difenoxin "INN", diphenoxylate "INN", dipipanone "INN", fentanyl "INN", ketobemidone "INN", methylphenidate "INN", pentazocine "INN", pethidine "INN", pethidine "INN" intermediate A, phencyclidine (inn) "pcp", phenoperidine (inn), pipradol (inn), piritramide (inn), propiram (inn) and trimeperidine (inn), and salts thereof | 4 | 6,5 % | 0 % [additional code 2500] / 6.5 % [additional code 2501] | 5,2 % | Franchiseà partir de 2030 |
| 2933 39 10 | Iproniazid "INN"; ketobemidone hydrochloride "INNM"; pyrodostigmine bromide "INN" | 0 | Franchise | Franchise | Franchise | Franchise |
| 2933 39 20 | 2,3,5,6-Tetrachloropyridine | 0 | Franchise | Franchise | Franchise | Franchise |
| 2933 39 25 | 3,6-Dichloropyridine-2-carboxylic acid | 0 | Franchise | Franchise | Franchise | Franchise |
| 2933 39 35 | 2-Hydroxyethylammonium-3,6-dichloropyridine-2-carboxylate | 0 | Franchise | Franchise | Franchise | Franchise |
| 2933 39 40 | 2-Butoxyethyl"3,5,6-trichloro-2-pyridyloxy"acetate | 0 | Franchise | Franchise | Franchise | Franchise |
| 2933 39 45 | 3,5-Dichloro-2,4,6-trifluoropyridine | 0 | Franchise | Franchise | Franchise | Franchise |
| 2933 39 50 | Fluroxypyr "ISO" methyl ester | 0 | 4 % | 4 % | Franchise | Franchise |
| 2933 39 55 | 4-Methylpyridine | 0 | Franchise | Franchise | Franchise | Franchise |
| 2933 39 99 | Heterocyclic compounds with nitrogen hetero-atom[s] only, containing an unfused pyridine ring, whether or not hydrogenated, in the structure (excl. pyridine, piperidine, alfentanil "INN", anileridine "INN", bezitramide "INN", bromazepam "INN", difenoxin "inn"», diphenoxylate (inn), dipipanone (inn), fentanyl (inn), ketobemidone (inn), methylphenidate (inn), pentazocine (inn), pethidine (inn), pethidine (inn) intermediate a, phencyclidine (inn) "pcp", phenoperidine (inn), pipradol (inn), piritramide (inn), propiram (inn), trimeperidine (inn), and their salts, and iproniazid (inn), ketobemidone hydrochloride "innm", pyridostigmine bromide (inn), 2,3,5,6-tetrachloropyridine, 3,6-dichloropyridine-2-carboxylic acid, 2-hydroxyethylammonium-3,6-dichloropyridine-2-carboxylate, 2- butoxyethyl"3,5,6-trichloro-2-pyridyloxy"acetate, 3,5-dichloro-2,4,6- trifluoropyridine, fluroxypyr (iso) methyl ester, 4-methylpyridine, and inorganic or organic compounds of mercury) | 4 | 6,5 % | 0 % [additional code 2500] / 6.5 % / 6.5 % [additional code 2501] | 5,2 % | Franchiseà partir de 2030 |
| 2933 41 00 | Levorphanol "INN" and its salts | 0 | Franchise | Franchise | Franchise | Franchise |
| 2933 49 10 | Halogen derivatives of quinoline; quinolinecarboxylic acid derivatives | 4 | 5,5 % | 0 % [additional code 2500] / 5.5 % / 5.5 % [additional code 2501] | 4,4 % | Franchiseà partir de 2030 |
| 2933 49 30 | Dextromethorphan "INN" and its salts | 0 | Franchise | Franchise | Franchise | Franchise |
| 2933 49 90 | Heterocyclic compounds with nitrogen hetero-atom[s] only, containing in the structure a quinoline or isoquinoline ring-system, whether or not hydrogenated, but not further fused (excl. levorphanol "INN", dextromethorphan "INN", and their salts, halogen derivatives of quinoline, quinolinecarboxylic acid derivatives, and inorganic or organic compounds of mercury) | 4 | 6,5 % | 0 % [additional code 2500] / 6.5 % / 6.5 % [additional code 2501] | 5,2 % | Franchiseà partir de 2030 |
| 2933 52 00 | Malonylurea "barbituric acid" and its salts | 4 | 6,5 % | 6,5 % | 5,2 % | Franchiseà partir de 2030 |
| 2933 53 10 | Phenobarbital "INN", barbital "INN", and salts thereof | 0 | Franchise | Franchise | Franchise | Franchise |
| 2933 53 90 | Allobarbital "INN", amobarbital "INN", butalbital "INN", butobarbital "INN", cyclobarbital "INN", methylphenobarbital "INN", pentobarbital "INN", secbutabarbital "INN", secobarbital "INN" and vinylbital "INN", and salts thereof | 4 | 6,5 % | 0 % [additional code 2500] / 6.5 % [additional code 2501] | 5,2 % | Franchiseà partir de 2030 |
| 2933 54 00 | Derivatives of malonylurea "barbituric acid" and salts thereof (excl. salts of malonylurea) | 4 | 6,5 % | 0 % [additional code 2500] / 6.5 % [additional code 2501] | 5,2 % | Franchiseà partir de 2030 |
| 2933 55 00 | Loprazolam "INN", mecloqualone "INN", methaqualone "INN" and zipeprol "INN", and salts thereof | 0 | Franchise | Franchise | Franchise | Franchise |
| 2933 59 10 | Diazinon "ISO" | 0 | Franchise | Franchise | Franchise | Franchise |
| 2933 59 20 | 1,4-Diazabicyclo[2.2.2]octane "triethylenediamine" | 0 | Franchise | Franchise | Franchise | Franchise |
| 2933 59 95 | Heterocyclic compounds with nitrogen hetero-atom"s" only, containing a pyrimidine ring, whether or not hydrogenated, or piperazine ring in the structure (excl. malonylurea "barbituric acid" and its derivatives, allobarbital "INN", amobarbital "INN", barbital (inn), butalbital (inn), butobarbital (inn), cyclobarbital (inn), methylphenobarbital (inn), pentobarbital (inn), phenobarbital (inn), secbutabarbital (inn), secobarbital (inn), vinylbital (inn), loprazolam (inn), mecloqualone (inn), methaqualone (inn) and zipeprol (inn), and salts thereof, and diazinon (iso) and 1,4-diazabicyclo[2.2.2]octane "triethylenediamine") | 4 | 6,5 % | 0 % [additional code 2500] / 6.5 % / 6.5 % [additional code 2501] | 5,2 % | Franchiseà partir de 2030 |
| 2933 61 00 | Melamine | 4 | 6,5 % | 6,5 % | 5,2 % | Franchiseà partir de 2030 |
| 2933 69 10 | Atrazine "ISO"; propazine "ISO"; simazine "ISO"; hexahydro-1,3,5-trinitro-1,3,5- triazine "hexogen, trimethylenetrinitramine" | 4 | 5,5 % | 5,5 % | 4,4 % | Franchiseà partir de 2030 |
| 2933 69 40 | Methenamine (INN) (hexamethylenetetramine); 2,6-Di-tert-butyl-4-[4,6- bis(octylthio)-1,3,5-triazine-2-ylamino]phenol | 0 | Franchise | Franchise | Franchise | Franchise |
| 2933 69 80 | Heterocyclic compounds with nitrogen hetero-atom[s] only, containing an unfused triazine ring, whether or not hydrogenated, in the structure (excl. melamine, atrazine "ISO", propazine "ISO", simazine "ISO", hexahydro-1,3,5-trinitro-1,3,5- triazine "hexogen, trimethylenetrinitramine", methenamine [inn] "hexamethylenetetramine" and 2,6-di-tert-butyl-4-[4,6-bis"octylthio"-1,3,5-triazine- 2-ylamino]phenol) | 4 | 6,5 % | 0 % [additional code 2500] / 6.5 % / 6.5 % [additional code 2501] | 5,2 % | Franchiseà partir de 2030 |
| 2933 71 00 | 6-Hexanelactam "epsilon-caprolactam" | 4 | 6,5 % | 6,5 % | 5,2 % | Franchiseà partir de 2030 |
| 2933 72 00 | Clobazam "INN" and methyprylon "INN" | 0 | Franchise | Franchise | Franchise | Franchise |
| 2933 79 00 | Lactams (excl. 6-hexanelactam "epsilon-caprolactam", clobazam "INN", methyprylon "INN", and inorganic or organic compounds of mercury) | 4 | 6,5 % | 0 % [additional code 2500] / 6.5 % / 6.5 % [additional code 2501] | 5,2 % | Franchiseà partir de 2030 |
| 2933 91 10 | Chlorodiazepoxide "INN" | 0 | Franchise | Franchise | Franchise | Franchise |
| 2933 91 90 | Alprazolam "INN", camazepam "INN", clonazepam "INN", clorazepate, delorazepam "INN", diazepam "INN", estazolam "INN", ethyl loflazepate "INN", fludiazepam "INN", flunitrazepam "INN", flurazepam "INN", halazepam "INN", lorazepam "INN", lormetazepam "INN", mazindol (inn), medazepam (inn), midazolam (inn), nimetazepam (inn), nitrazepam (inn), nordazepam (inn), oxazepam (inn), pinazepam (inn), prazepam (inn), pyrovalerone (inn), temazepam (inn), tetrazepam (inn) and triazolam (inn), salts thereof, and salts of chlordiazepoxide (inn) | 4 | 6,5 % | 0 % [additional code 2500] / 6.5 % [additional code 2501] | 5,2 % | Franchiseà partir de 2030 |
| 2933 99 20 | Indole, 3-methylindole "skatole", 6-allyl-6,7-dihydro-5H-dibenz"c,e"azepine "azapetine", phenindamine "INN" and their salts; imipramine hydrochloride "INNM" | 4 | 5,5 % | 0 % [additional code 2500] / 5.5 % [additional code 2501] | 4,4 % | Franchiseà partir de 2030 |
| 2933 99 50 | 2,4-Di-tert-butyl-6-"5-chlorobenzotriazol-2-yl"phenol | 0 | Franchise | Franchise | Franchise | Franchise |
| 2933 99 80 | Heterocyclic compounds with nitrogen hetero-atom[s] only (excl. those containing an unfused pyrazole, imidazole, pyridine or triazine ring, whether or not hydrogenated, a quinoline or isoquinoline ring-system, not further fused, whether or not hydrogenate, or piperazine ring in the structure, lactams, alprazolam (inn), camazepam (inn), chlordiazepoxide (inn), clonazepam (inn), clorazepate, delorazepam (inn), diazepam (inn), estazolam (inn), ethyl loflazepate (inn), fludiazepam (inn), flunitrazepam (inn), flurazepam (inn), halazepam (inn), lorazepam (inn), lormetazepam (inn), mazindol (inn), medazepam (inn), midazolam (inn), nimetazepam (inn), nitrazepam (inn), nordazepam (inn), oxazepam (inn), pinazepam (inn), prazepam (inn), pyrovalerone (inn), temazepam (inn), tetrazepam (inn), triazolam (inn), salts thereof, indole, 3-methylindole "skatole", 6-allyl-6,7- dihydro-5h-dibenz"c,e"azepine "azapetine", phenindamine (inn) and their salts, imipramine hydrochloride "innm", 2,4-di-tert-butyl-6-"5-chlorobenzotriazol-2- yl"phenol) | 4 | 6,5 % | 0 % [additional code 2500] / 6.5 % / 6.5 % [additional code 2501] | 5,2 % | Franchiseà partir de 2030 |
Vers le Brésil depuis l’UE : 243 lignes
| Code | Désignation | Catégorie | Base | NPF appliqué | 2026 | Final |
|---|---|---|---|---|---|---|
| 2933 11 11 | Dipyrone | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 11 12 | Magnopyrol | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 11 19 | Other 1-Phenyl-2,3-dimethyl-5-pyrazolone-4- methylaminomethanesulfonic acid and its salts, except dipyrone and magnopirol ("magnesium dipyrone") | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 11 20 | Methylenebis(4-methylamino-1-phenyl-2, 3-dimethyl)pyraz. | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 11 90 | Other phenazone (antipyrin) and its derivatives | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 19 11 | Phenylbutazone calcium | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 19 19 | Other phenylbutazone, its salts | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 19 90 | Other heterocyclic compounds with 1 cycle pyrazole, not condensed | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 21 10 | Iprodione | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 21 21 | Phenytoin and its sodium salt | 10 | 14 % | 12,6 % | 11,4 % | Franchiseà partir de 2036 |
| 2933 21 29 | Other phenytoin salts | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 21 90 | Other hydantoin and its derivatives | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 29 11 | 2-metil-5-nitroimidazol | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 29 12 | Metronidazole and its salts | 10 | 14 % | 12,6 % | 11,4 % | Franchiseà partir de 2036 |
| 2933 29 13 | Tinidazole | 10 | 14 % | 12,6 % | 11,4 % | Franchiseà partir de 2036 |
| 2933 29 19 | Other heterocyclic compounds with 1 nitroimidazole | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 29 21 | Econazole and its nitrate | 10 | 14 % | 12,6 % | 11,4 % | Franchiseà partir de 2036 |
| 2933 29 22 | Miconazol nitrate | 10 | 14 % | 12,6 % | 11,4 % | Franchiseà partir de 2036 |
| 2933 29 23 | Clonidine hydrochloride | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 29 24 | Isoconazole nitrate | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 29 25 | Clotrimazole | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 29 29 | Heterocyclic compounds with chlorinated benzene cycle | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 29 30 | Cimetidine and its salts | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 29 40 | 4-methyl-5-hydroxymethylimidazole and its salts | 10 | 12 % | 10,8 % | 9,8 % | Franchiseà partir de 2036 |
| 2933 29 91 | Imidazole | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 29 92 | Histidine and its salts | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 29 93 | Ondansetron and its salts | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 29 94 | 1-hydroxyethyl-2-undecanoylimidazoline | 10 | 12 % | 10,8 % | 9,8 % | Franchiseà partir de 2036 |
| 2933 29 95 | 1-hydroxyethyl-2-(8- heptadecanoyl)imidazoline | 10 | 12 % | 10,8 % | 9,8 % | Franchiseà partir de 2036 |
| 2933 29 99 | Other heterocyclic compounds 1 cycle imidazole not condensed | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 31 10 | Pyridine | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 31 20 | Salts of pyridine | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 32 00 | Piperidine and its salts | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 33 11 | Alfentanil | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 33 12 | Anileridine | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 33 19 | Salts of alfentanil or anileridine | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 33 21 | Bezitramide | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 33 22 | Bromazepam | 10 | 12 % | 10,8 % | 9,8 % | Franchiseà partir de 2036 |
| 2933 33 29 | Salts of bezitramida or bromazepam | 0 | 2 % | Franchise | Franchise | Franchise |
| 2933 33 30 | Ketobemidone and its salts | 4 | 2 % | – | 1,6 % | Franchiseà partir de 2030 |
| 2933 33 41 | Diphenoxylate | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 33 42 | Diphenoxylate hydrochloride | 10 | 14 % | 12,6 % | 11,4 % | Franchiseà partir de 2036 |
| 2933 33 49 | Other diphenoxylate salts | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 33 51 | Diphenoxin | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 33 52 | Dipipanone | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 33 59 | Salts of difenoxin or dipipanona | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 33 61 | Phencyclidine | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 33 62 | Phenoperidine | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 33 63 | Fentanyl | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 33 69 | Salts of phencyclidine, phenoperidine or fentanyl | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 33 71 | Methylphenidate | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 33 72 | Pentazocine | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 33 79 | Salts of methylphenidate or pentazocine | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 33 81 | Pethidine | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 33 82 | Pethidine intermediate | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 33 83 | Pipradrol | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 33 84 | Pethidine hycrochloride | 10 | 14 % | 12,6 % | 11,4 % | Franchiseà partir de 2036 |
| 2933 33 89 | Other salts of pethidine or of intermediate A of pethidine and pipradol | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 33 91 | Piritramide | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 33 92 | Propiram | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 33 93 | Trimeperidine | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 33 99 | Other of piritramide or trimeperidine | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 39 12 | Droperidol | 10 | 12 % | 10,8 % | 9,8 % | Franchiseà partir de 2036 |
| 2933 39 13 | Niflumic acid | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 39 14 | Haloxifop (rs)-2-[4-(3-chloro-5- trifluoromethyl-etc | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 39 15 | Haloperidol | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 39 19 | Other heterocyclic compounds which structure contains fluorine, bromine, or both, in covalent bond | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 39 21 | Picloram | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 39 22 | Chlorpyrifos | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 39 23 | Clebopride malate acid | 10 | 14 % | 12,6 % | 11,4 % | Franchiseà partir de 2036 |
| 2933 39 24 | Cloperamide hydrochloride | 10 | 14 % | 12,6 % | 11,4 % | Franchiseà partir de 2036 |
| 2933 39 25 | (2-methyl-3-chloroaniline)nicotinic acid/lysine salts | 10 | 14 % | 12,6 % | 11,4 % | Franchiseà partir de 2036 |
| 2933 39 29 | Other heterocyclic compounds which structure contains chlorine but does not contain fluorine or bromine, in a covalent bond | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 39 31 | Terfenadine | 10 | 14 % | 12,6 % | 11,4 % | Franchiseà partir de 2036 |
| 2933 39 32 | Biperiden and its salts | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 39 33 | Isonicotinic acid | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 39 34 | 5-ethyl-2, 3-dicarboxypyridine (5-epdc) | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 39 35 | Mazetapir (rs)-5-ethyl-2-(4-isopropyl-4- methyl-5-etc. | 15 | 14 % | 12,6 % | 11,8 % | Franchiseà partir de 2041 |
| 2933 39 36 | Quinuclidine-3-ol | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 39 39 | Pentazocine and its salts | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 39 43 | Nifedipine | 10 | 14 % | 12,6 % | 11,4 % | Franchiseà partir de 2036 |
| 2933 39 44 | Nitrendipine | 10 | 14 % | 12,6 % | 11,4 % | Franchiseà partir de 2036 |
| 2933 39 45 | Pirilamine maleate | 10 | 14 % | 12,6 % | 11,4 % | Franchiseà partir de 2036 |
| 2933 39 46 | Omeprazole | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 39 47 | 3-quinuclidinyl benzylate | 4 | 2 % | – | 1,6 % | Franchiseà partir de 2030 |
| 2933 39 48 | Nimodipine | 10 | 12 % | 10,8 % | 9,8 % | Franchiseà partir de 2036 |
| 2933 39 49 | Other compounds which structure contains ether, ester, or both functions, but does not contain alcohol or carboxylic acid functions or covalently bonded halogens | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 39 81 | Benzetamide hydrochloride | 10 | 14 % | 12,6 % | 11,4 % | Franchiseà partir de 2036 |
| 2933 39 82 | Mepivacaine hydrochloride | 10 | 14 % | 12,6 % | 11,4 % | Franchiseà partir de 2036 |
| 2933 39 83 | Bupivacaine hydrochloride | 10 | 14 % | 12,6 % | 11,4 % | Franchiseà partir de 2036 |
| 2933 39 84 | Paraquat dichloride | 10 | 12 % | 10,8 % | 9,8 % | Franchiseà partir de 2036 |
| 2933 39 89 | Other heterocyclic compounds which structure contains a piridine cycle (hydrogenated or not) N-substituted with alkyl or aryl radicals | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 39 91 | Phenazopyridine hydrochloride | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 39 92 | Isoniazid | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 39 93 | 3-cyanopyridine | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 39 94 | 4, 4'-bipiridine | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 39 99 | Other heterocyclic compounds 1 cycle piridine not condensed | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 41 10 | Levorphanol | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 41 20 | Salts of levorphanol | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 49 11 | 2, 3-quinolinedicarboxylic acid | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 49 12 | Rosoxacin | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 49 13 | I-mazaquin | 10 | 14 % | 12,6 % | 11,4 % | Franchiseà partir de 2036 |
| 2933 49 19 | Other derivatives of quinolinedicarboxylic acid | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 49 20 | Oxamniquine | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 49 30 | Broxyquinoline | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 49 40 | Esters of levorphanol | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 49 90 | Other compounds which structure contains cycles of quinoleine | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 52 00 | Malonylurea (barbituric acid) and its salts | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 53 11 | Allobarbital and its salts | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 53 12 | Amobarbital and its salts | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 53 21 | Barbital and its salts | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 53 22 | Butalbital and its salts | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 53 23 | Butethal and its salts | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 53 30 | Cyclobarbital and its salts | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 53 40 | Phenobarbital and its salts | 10 | 14 % | 12,6 % | 11,4 % | Franchiseà partir de 2036 |
| 2933 53 50 | Methylphenobarbital and its salts | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 53 60 | Pentobarbital and its salts | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 53 71 | Secbutabarbital and its salts | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 53 72 | Secobarbital and its salts | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 53 80 | Vinylbital and its salts | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 54 00 | Other derivatives of malonylurea (barbituric acid) | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 55 10 | Loprazolam and its salts | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 55 20 | Mecloqualone and its salts | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 55 30 | Methaqualone and its salts | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 55 40 | Zipeprol and its salts | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 59 11 | Oxatomide | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 59 12 | Praziquantel | 10 | 14 % | 12,6 % | 11,4 % | Franchiseà partir de 2036 |
| 2933 59 13 | Norfloxacin and its nicotinate | 0 | 2 % | Franchise | Franchise | Franchise |
| 2933 59 14 | Flunarizine and its dihydrochloride | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 59 15 | Enrofloxacin, piperazine salts | 10 | 12 % | 10,8 % | 9,8 % | Franchiseà partir de 2036 |
| 2933 59 16 | Buspirone hydrochloride | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 59 19 | Other heterocyclic compounds with piperazine ring | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 59 21 | Bromacyl | E | 14 % | 12,6 % | 12,6 % | 12,6 % |
| 2933 59 22 | Terbacil | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 59 23 | Fluorouracil | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 59 29 | Other heterocyclic compound, pirimidine cycles, halogens in covalent bond | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 59 31 | Propythiouracil | 10 | 14 % | 12,6 % | 11,4 % | Franchiseà partir de 2036 |
| 2933 59 32 | Diazinon | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 59 33 | Pyrazophs | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 59 34 | Azathioprine | 10 | 14 % | 12,6 % | 11,4 % | Franchiseà partir de 2036 |
| 2933 59 35 | 6-mercaptopurine | 10 | 14 % | 12,6 % | 11,4 % | Franchiseà partir de 2036 |
| 2933 59 39 | Other heterocyclic compounds, sulphur, without halogens in covalent bond | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 59 41 | Trimethoprim | 10 | 14 % | 12,6 % | 11,4 % | Franchiseà partir de 2036 |
| 2933 59 42 | Acyclovir | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 59 43 | Dipiridamol tosylates | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 59 44 | Nicarbazine | 10 | 14 % | 12,6 % | 11,4 % | Franchiseà partir de 2036 |
| 2933 59 45 | Menadione dimethylpyramidinol bisulphite | 8 | 8 % | 7,2 % | 6,4 % | Franchiseà partir de 2034 |
| 2933 59 49 | Other heterocyclic compound pyrimidine cycle, alcohol/ether functions | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 59 91 | Minoxidil | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 59 92 | 2-aminopyrimidine | 10 | 14 % | 12,6 % | 11,4 % | Franchiseà partir de 2036 |
| 2933 59 99 | Other heterocyclic compound with pyrimidine/piperazine cycle | 0 | 2 % | Franchise | Franchise | Franchise |
| 2933 61 00 | Melamine | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 69 11 | 2, 4, 6-trichlorotriazine (cyanuric chloride) | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 69 12 | Mercaptodichlorotriazine | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 69 13 | Atrazine | 10 | 12 % | 10,8 % | 9,8 % | Franchiseà partir de 2036 |
| 2933 69 14 | Simazine | 10 | 12 % | 10,8 % | 9,8 % | Franchiseà partir de 2036 |
| 2933 69 15 | Cyanazine | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 69 16 | Anilazine | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 69 19 | Other heterocyclic compound triazine cycle with chlorine covalent bond | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 69 21 | N, n, n-trihydroxyethylhexahydrotriazine | 10 | 14 % | 12,6 % | 11,4 % | Franchiseà partir de 2036 |
| 2933 69 22 | Hexazinon | 4 | Franchise | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 69 23 | Metribuzin | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 69 29 | Other heterocyclic compounds triazine cycle without chlorine covalent bond | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 69 91 | Ametryn | 10 | 2 % | Franchise | Franchise | Franchiseà partir de 2036 |
| 2933 69 92 | Methenamine (hexamethenamine) and its salts | 10 | 14 % | 12,6 % | 11,4 % | Franchiseà partir de 2036 |
| 2933 69 99 | Other heterocyclic compounds 1 triazine cycle not condensed | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 71 00 | 6-hexanelactam (epsilon-caprolactam) | 10 | 12 % | Franchise | Franchise | Franchiseà partir de 2036 |
| 2933 72 10 | Clobazam | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 72 20 | Methyprylon | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 79 10 | Piracetam | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 79 90 | Other lactams | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 91 11 | Alprazolam | 10 | 12 % | 10,8 % | 9,8 % | Franchiseà partir de 2036 |
| 2933 91 12 | Camazepam | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 91 13 | Clonazepam | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 91 14 | Clorazepate | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 91 15 | Chlordiazapoxide | 10 | 12 % | 10,8 % | 9,8 % | Franchiseà partir de 2036 |
| 2933 91 19 | Salts of alprazolam, camazepam, clonazepam, clorazepate and chlordiazepoxide | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 91 21 | Delorazepam | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 91 22 | Diazepam | 10 | 14 % | 12,6 % | 11,4 % | Franchiseà partir de 2036 |
| 2933 91 23 | Estazolam | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 91 29 | Salts of delorazepam, diazepam or estazolam | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 91 31 | Fludiazepam | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 91 32 | Flunitrazepam | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 91 33 | Flurazepam | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 91 34 | Halazepam | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 91 39 | Salts of fludiazepam, flunitrazepam, flurazepam and halazepam | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 91 41 | Ethyl loflazepate | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 91 42 | Lorazepam | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 91 43 | Lormetazepam | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 91 49 | Salts of ethyl loflazepate, lorazepam, and lormetazepam | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 91 51 | Mazindol | 10 | 14 % | 12,6 % | 11,4 % | Franchiseà partir de 2036 |
| 2933 91 52 | Medazepam | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 91 53 | Midazolam | 10 | 14 % | 12,6 % | 11,4 % | Franchiseà partir de 2036 |
| 2933 91 59 | Salts of mazindol, medazepam or midazolam | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 91 61 | Nimetazepam | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 91 62 | Nitrazepam | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 91 63 | Nordazepam | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 91 64 | Oxazepam | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 91 69 | Salts of nimetazepam, nitrazepam, nordazepam, oxazepam | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 91 71 | Pinazepam | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 91 72 | Pyrovalerone | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 91 73 | Prazepam | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 91 79 | Salts of pinazepam, pirovalerona or prazepam | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 91 81 | Temazepam | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 91 82 | Tetrazepam | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 91 83 | Triazolam | 10 | 12 % | 10,8 % | 9,8 % | Franchiseà partir de 2036 |
| 2933 91 89 | Salts of temazepam, tetrazepam and triazolam | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 99 11 | Pyrazinamide | 10 | 14 % | 12,6 % | 11,4 % | Franchiseà partir de 2036 |
| 2933 99 12 | Amiloride hydrochloride | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 99 13 | Pindolol | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 99 19 | Other heterocyclic compounds which structure contains an uncondensed pyrazine cycle or indole cycles (hydrogenated or not) without other condensations | 4 | 2 % | 10,8 % | 1,6 % | Franchiseà partir de 2030 |
| 2933 99 20 | Other heterocyclic compounds which structure contains diazepine cycle (hydrogenated or not) | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 99 31 | Iminostilbene | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 99 32 | Carbamazepine | 10 | 14 % | 12,6 % | 11,4 % | Franchiseà partir de 2036 |
| 2933 99 33 | Clomipramine hydrochloride | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 99 34 | Molinate (s-ethyl hexahydroazepin-1- carbothioate) | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 99 35 | Hexamethyleneimine | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 99 39 | Other heterocyclic compounds which structure contains azepine cycle (hydrogenated or not) | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 99 41 | Clemastine, its derivatives and its salts | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 99 42 | Amisulpride | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 99 43 | Sultopride | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 99 44 | Alizapride | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 99 45 | Buflomedil its derivatives and its salts | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 99 46 | Enalapril maleate | 10 | 14 % | 12,6 % | 11,4 % | Franchiseà partir de 2036 |
| 2933 99 47 | Ketorolac tromethamine salt | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 99 49 | Other heterocyclic compounds which structure contains pyrrole cycle (hydrogenated or not) | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 99 51 | Benomyl | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 99 52 | Oxfendazole | 10 | 14 % | 12,6 % | 11,4 % | Franchiseà partir de 2036 |
| 2933 99 53 | Albendazole and albendazole sulphoxide | 10 | 14 % | 12,6 % | 11,4 % | Franchiseà partir de 2036 |
| 2933 99 54 | Mebendazole | 10 | 14 % | 12,6 % | 11,4 % | Franchiseà partir de 2036 |
| 2933 99 55 | Flubendazole | 10 | 14 % | 12,6 % | 11,4 % | Franchiseà partir de 2036 |
| 2933 99 56 | Fembendazole | 10 | 14 % | 12,6 % | 11,4 % | Franchiseà partir de 2036 |
| 2933 99 59 | Other heterocyclic compounds which structure contains imidazole cycle (hydrogenated or not) | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 99 61 | Triadimenol | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 99 62 | Triadimefon | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 99 63 | Triazofos(O, O-diethyl O-(1-phenyl -1H- 1,2,4-triazol-3-yl) phosphorothioate) | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 99 69 | Otherheterocyclic compounds which structure contains a triazole cycle (hydrogenated or not), not condensed | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 99 91 | Azinfos-ethyl | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 99 92 | Nalidixic acid | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
| 2933 99 93 | Clofazimine | 10 | 14 % | 12,6 % | 11,4 % | Franchiseà partir de 2036 |
| 2933 99 95 | Amezinium methyl sulphate | 10 | 14 % | 12,6 % | 11,4 % | Franchiseà partir de 2036 |
| 2933 99 96 | Maleic hydrazide and its salts | 10 | 12 % | 10,8 % | 9,8 % | Franchiseà partir de 2036 |
| 2933 99 99 | Other heterocyclic compounds with nitrogen hetero-atom | 4 | 2 % | Franchise | Franchise | Franchiseà partir de 2030 |
Produits associés
- 2905Alcools acycliques
- 2918Acides carboxyliques à fonctions oxygénées supplémentaires
- 3002Vaccins, sang et produits immunologiques
- 3003Médicaments en vrac
- 3004Médicaments en doses
- 2836Carbonates
Toutes les positions du chapitre 29: Produits chimiques organiques
Données et méthode
Calculé avec le moteur du calculateur à partir des listes de l’accord (annexe 2-A) et des fichiers de taux appliqués, pour l’année 2026 de l’accord. Les chiffres Mercosur → UE supposent une origine brésilienne, ce qui ne compte que pour les quelques contingents propres à une origine ; les chiffres UE → Mercosur valent pour le Brésil, sauf indication contraire dans le tableau par pays.
- EU TARIC via Swedish Customs Tariff File Distribution (TF), 16 octobre 2026
- Brazil applied import duty, Res. Gecex 272/2021 Annexes II, V, VI, IX (MDIC), 5 octobre 2026
- Argentina applied import duty (DIE), ARCA Arancel Integrado, 18 octobre 2026
- Uruguay applied import duty (Arancel Nacional, MEF), 10 février 2025 · Copie manuelle · Plus de 180 jours
- Paraguay applied import duty (Arancel Nacional Vigente, MEF), 4 novembre 2025 · Copie manuelle · Plus de 180 jours
Méthodologie et sources des données
Estimations uniquement, sans valeur de conseil juridique ou douanier. Vérifiez les listes officielles avant de vous fier à un taux.